July 2010
M	T	W	T	F	S	S
« Apr		Aug »
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Home

1A binding reductions in euthymic bipolar disorder patients]]>

Posted by admin on July 25th, 2010

25
Jul

5-HT_1A receptor binding is not reduced in medicated euthymic bipolar disorder patients versus healthy individuals, say researchers in findings that contrast with the reductions seen in unipolar and bipolar depressed patients.

Previous studies of 5-HT_1A receptor binding have focused on unipolar and bipolar depressed patients, with mixed results, but the greatest reductions observed have been in patients with a family history of bipolar disorder.

To examine binding reductions in euthymic bipolar disorder patients, Peter Sargent, from Warneford Hospital in Oxford, UK, and colleagues performed positron emission tomography using the selective 5-HT_1A receptor ligand [carbonyl-¹¹C]WAY-100635 in eight medicated euthymic bipolar disorder patients and eight healthy controls.

Although the team found a significant negative correlation between age and global postsynaptic parametric binding potential, there was no significant difference in binding potential between patients and controls, at averages of 4.24 and 4.34, respectively.

The results, published in the Journal of Affective Disorders, also demonstrated no significant differences in regional parametric binding potentials between the groups. There was no significant correlation between global binding potentials and depression scores in patients.

The team concludes: “Longitudinal studies examining 5-HT_1A binding in both medicated and unmedicated patients with bipolar disorder are warranted to clarify whether there may be effects of medication on 5-HT_1A binding or whether there is an effect of mood state in bipolar disorder with normalization of 5-HT_1A binding in the euthymic state.”

MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009